139 ( 27 % ) patients had disease-free survival events in the adjuvant capecitabine and oxaliplatin group versus 203 ( 39 % ) patients in the observation group ( stratified hazard ratio [ HR ] 058 , 95 % CI 047-072 ; p < 00001 ) .